CIANNIELLO, DANIELA
 Distribuzione geografica
Continente #
NA - Nord America 63
EU - Europa 47
AS - Asia 43
AF - Africa 2
SA - Sud America 1
Totale 156
Nazione #
US - Stati Uniti d'America 60
IT - Italia 38
SG - Singapore 17
HK - Hong Kong 14
CN - Cina 10
CA - Canada 3
CI - Costa d'Avorio 2
FR - Francia 2
GB - Regno Unito 2
IE - Irlanda 2
IN - India 2
RU - Federazione Russa 2
EC - Ecuador 1
LT - Lituania 1
Totale 156
Città #
Hong Kong 14
Singapore 14
Chandler 12
Napoli 10
Santa Clara 8
Salerno 5
Afragola 4
Ashburn 4
Beijing 2
Nanjing 2
Princeton 2
Pune 2
Seattle 2
Wilmington 2
Arzano 1
Bacoli 1
Boardman 1
Boston 1
Des Moines 1
Edinburgh 1
Fort St. James 1
Linfen 1
London 1
Millbury 1
Moscow 1
Nanchang 1
Naples 1
Quito 1
Sant'Agnello 1
Shenyang 1
Sicignano Degli Alburni 1
Tianjin 1
Toronto 1
Vancouver 1
Venetico 1
Totale 104
Nome #
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results 58
Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: A multicenter study 33
Uptake of trastuzumab biosimilars for the treatment of her2-positive breast cancer: A real-world experience from a cancer center 25
Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial 24
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 23
Totale 163
Categoria #
all - tutte 887
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 887


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203 0 0 0 0 0 0 0 1 0 1 1 0
2020/20217 0 0 0 0 0 0 1 0 5 1 0 0
2021/202210 0 0 0 0 0 0 0 1 2 2 1 4
2022/202329 2 0 1 3 4 4 0 3 5 1 6 0
2023/202427 3 5 2 4 0 2 1 4 0 0 4 2
2024/202551 5 2 0 1 8 11 24 0 0 0 0 0
Totale 163